Javascript must be enabled to continue!
Association between levodopa and ischemic heart disease
View through CrossRef
Background Several studies linked the use of levodopa to an increase in homocysteine level, which can lead eventually to ischemic heart disease (IHD) in Parkinson’s disease (PD) patients. There is a lack of large population studies that have investigated the cardiovascular safety of levodopa.
Objectives The main objective of the study is to investigate the one-year risk of IHD hospitalisation, all-cardiovascular hospital hospitalisation, and all-cause mortality among users of L-dopa compared with users of Monoamine oxidase B (MAO-B) inhibitors (as a reference).
Methods A population-based study evaluated data obtained from the Secure Anonymised Information Linkage (SAIL) Databank of residents in Wales, aged 40 years or older, newly treated with PD medications between 2000 and 2016. The General Practice (GP) database was used to identify the PD diagnostic codes, PD medications, and other medications used by PD patients. Hospital data were used to identify the first hospitalisation event (IHD and other cardiovascular events). A fully adjusted propensity score multivariate Cox regression analysis was used to examine associations between levodopa and the study outcomes. The index date was set at the date of the first PD prescription in the newly diagnosed PD patients. Other variables included gender, comorbidities, social deprivation score and previous medications history were controlled for.
Findings There were 5,140 participants on levodopa and 494 on MAO-B inhibitors. L-dopa was not associated with IHD (p=0.561), other cardiovascular events (p=0.233), or all-cause mortality (p=0.334). For IHD, the lack of difference was seen also in the unadjusted model and in the age-only adjusted model.
Conclusion This study has shown that L-dopa does not increase the risk of IHD, cardiovascular risk, or all-cause mortality in the newly diagnosed PD patient within one year after the therapy initiation. This could contribute to the safety profile of L-dopa therapy. Future research with a longer follow up period is warranted.
Title: Association between levodopa and ischemic heart disease
Description:
Background Several studies linked the use of levodopa to an increase in homocysteine level, which can lead eventually to ischemic heart disease (IHD) in Parkinson’s disease (PD) patients.
There is a lack of large population studies that have investigated the cardiovascular safety of levodopa.
Objectives The main objective of the study is to investigate the one-year risk of IHD hospitalisation, all-cardiovascular hospital hospitalisation, and all-cause mortality among users of L-dopa compared with users of Monoamine oxidase B (MAO-B) inhibitors (as a reference).
Methods A population-based study evaluated data obtained from the Secure Anonymised Information Linkage (SAIL) Databank of residents in Wales, aged 40 years or older, newly treated with PD medications between 2000 and 2016.
The General Practice (GP) database was used to identify the PD diagnostic codes, PD medications, and other medications used by PD patients.
Hospital data were used to identify the first hospitalisation event (IHD and other cardiovascular events).
A fully adjusted propensity score multivariate Cox regression analysis was used to examine associations between levodopa and the study outcomes.
The index date was set at the date of the first PD prescription in the newly diagnosed PD patients.
Other variables included gender, comorbidities, social deprivation score and previous medications history were controlled for.
Findings There were 5,140 participants on levodopa and 494 on MAO-B inhibitors.
L-dopa was not associated with IHD (p=0.
561), other cardiovascular events (p=0.
233), or all-cause mortality (p=0.
334).
For IHD, the lack of difference was seen also in the unadjusted model and in the age-only adjusted model.
Conclusion This study has shown that L-dopa does not increase the risk of IHD, cardiovascular risk, or all-cause mortality in the newly diagnosed PD patient within one year after the therapy initiation.
This could contribute to the safety profile of L-dopa therapy.
Future research with a longer follow up period is warranted.
Related Results
Genetic silencing of striatal CaV1.3 prevents and ameliorates levodopa dyskinesia
Genetic silencing of striatal CaV1.3 prevents and ameliorates levodopa dyskinesia
AbstractBackgroundLevodopa‐induced dyskinesias are an often debilitating side effect of levodopa therapy in Parkinson's disease. Although up to 90% of individuals with PD develop t...
COVID impact on pattern of ischemic heart disease in comparable period
COVID impact on pattern of ischemic heart disease in comparable period
Aim: To compare the impact of COVID-19 on pattern of Ischemic Heart Disease in comparable period by assessing the incidence, severity of symptoms and in-hospital mortality of Ische...
An Overview of Levodopa in the Management of Restless Legs Syndrome in a Dialysis Population: Pharmacokinetics, Clinical Trials, and Complications of Therapy
An Overview of Levodopa in the Management of Restless Legs Syndrome in a Dialysis Population: Pharmacokinetics, Clinical Trials, and Complications of Therapy
OBJECTIVE: To review published literature investigating the efficacy and safety of levodopa in the management of restless legs syndrome (RLS), with emphasis on the hemodialysis pop...
Levodopa treatment and dendritic spine pathology
Levodopa treatment and dendritic spine pathology
ABSTRACTParkinson's disease (PD) is a neurodegenerative disorder associated with the progressive loss of nigrostriatal dopaminergic neurons. Levodopa is the most effective treatmen...
Involuntary Movements
Involuntary Movements
Abstract
Choreiform involuntary movements, “dyskinesia,” are a manifestation of chronic levodopa treatment in Parkinson’s disease. Levodopa-induced chorea presents a...
Duloxetine increases the effects of levodopa in a rat model of Parkinson's disease
Duloxetine increases the effects of levodopa in a rat model of Parkinson's disease
AbstractBackgroundIn patients with advanced Parkinson's disease, serotonergic and noradrenergic systems act as surrogates for the failing dopaminergic system. Treatment with a sero...
GENETIC PERSPECTIVE OF THE CONGENITAL HEART DISEASE
GENETIC PERSPECTIVE OF THE CONGENITAL HEART DISEASE
Congenital heart diseases (CHDs) are the structural abnormalities that may occur in the heart, greater veins and arteries or may include the septum between the ventricles and atria...
Development and Validation of UV-Visible Spectrophotometric Method for Estimation of Levodopa
Development and Validation of UV-Visible Spectrophotometric Method for Estimation of Levodopa
Aim: The aim of the proposed study was to development and validation of simple, accurate, precise yet economical UV-Visible spectrophotometric method for the quantitative estimatio...

